Clinigen Group PLC (LON:CLIN) insider Nick Keher purchased 3,900 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was bought at an average cost of GBX 893 ($11.67) per share, with a total value of £34,827 ($45,507.64).

Shares of LON:CLIN traded up GBX 40 ($0.52) during midday trading on Thursday, hitting GBX 923.50 ($12.07). The company had a trading volume of 399,673 shares, compared to its average volume of 432,646. The business’s 50-day simple moving average is GBX 920.66 and its 200-day simple moving average is GBX 963.55. The company has a debt-to-equity ratio of 56.71, a current ratio of 1.54 and a quick ratio of 1.32. The stock has a market cap of $1.23 billion and a price-to-earnings ratio of 46.41. Clinigen Group PLC has a twelve month low of GBX 716 ($9.36) and a twelve month high of GBX 1,069 ($13.97).

Several research firms recently commented on CLIN. Peel Hunt reaffirmed a “buy” rating and issued a GBX 1,390 ($18.16) price target on shares of Clinigen Group in a report on Wednesday, June 26th. Peel Hunt reaffirmed a “buy” rating on shares of Clinigen Group in a report on Thursday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 1,371 ($17.91).

Clinigen Group Company Profile

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.

Read More: What are Bollinger Bands?

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.